In a filing, Schrodinger Inc revealed its President of R&D, Therapeutics Akinsanya Karen unloaded Company’s shares for reported $0.42 million on Apr 14 ’25. In the deal valued at $25.09 per share,16,723 shares were sold. As a result of this transaction, Akinsanya Karen now holds 15,625 shares worth roughly $0.32 million.
Then, Karen Akinsanya bought 16,723 shares, generating $409,546 in total proceeds.
Before that, Herman Jenny sold 666 shares. Schrodinger Inc shares valued at $14,059 were divested by the SVP & Controller at a price of $21.11 per share. As a result of the transaction, Herman Jenny now holds 27,349 shares, worth roughly $0.56 million.
A number of analysts have revised their coverage, including Leerink Partners’s analysts, who began to cover the stock in early July with a ‘”an Outperform”‘ rating. KeyBanc Capital Markets began covering SDGR with “an Overweight” recommendation on December 05, 2023.
Price Performance Review of SDGR
On Tuesday, Schrodinger Inc [NASDAQ:SDGR] saw its stock fall -3.64% to $20.37. Over the last five days, the stock has lost -4.90%. Schrodinger Inc shares have fallen nearly -5.52% since the year began. Nevertheless, the stocks have risen 5.60% over the past one year. While a 52-week high of $28.47 was reached on 02/18/25, a 52-week low of $16.60 was recorded on 04/07/25.
Levels Of Support And Resistance For SDGR Stock
The 24-hour chart illustrates a support level at 19.90, which if violated will result in even more drops to 19.42. On the upside, there is a resistance level at 21.10. A further resistance level may holdings at 21.82.
How much short interest is there in Schrodinger Inc?
A steep rise in short interest was recorded in Schrodinger Inc stocks on 2025-06-13, growing by 0.27 million shares to a total of 10.48 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 10.22 million shares. There was a rise of 2.55%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 19, 2022 when Goldman began covering the stock and recommended ‘”a Neutral”‘ rating along with a $23 price target.
